Invivyd Inc (IVVD)

$2.81 +0.01 (0.36%)
Market Cap 652.74M
Revenue (ttm) 25.38M
Net Income (ttm) -169.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -669.54%
Debt to Equity Ratio 0.00
Volume 4,034,700
Avg Vol 7,883,850
Day's Range N/A - N/A
Shares Out 233.12M
Stochastic %K 76%
Beta 0.61
Analysts Strong Sell
Price Target $10.00

Company Profile

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in pha...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 819 0080
Website: invivyd.com
Address:
1601 Trapelo Road, Suite 178, Waltham, United States
RunnerSignals
RunnerSignals Dec. 24 at 9:29 PM
Comeback Kings Watch $TMC $IVVD $SES $SGML $LODE They tagged the lows, shook it off, and finished higher
0 · Reply
SpecialOfficer
SpecialOfficer Dec. 24 at 3:58 PM
$IVVD not even 6,000 followers We early folks
0 · Reply
SpecialOfficer
SpecialOfficer Dec. 24 at 3:52 PM
$IVVD looks solid!! Picked up a few thousand shares 😝
0 · Reply
gb2017384
gb2017384 Dec. 24 at 3:06 PM
$IVVD THIS WHAT YOU GET AFTER A STRONG BUY RATING THE USUAL SUCKER BET$$$$
0 · Reply
JarvisFlow
JarvisFlow Dec. 24 at 11:01 AM
BTIG updates rating for Invivyd ( $IVVD ) to Buy, target set at 10.
0 · Reply
ExecutionerRex
ExecutionerRex Dec. 24 at 10:10 AM
$IVVD Forward visibility remains uneven as execution velocity aligns with stated operational milestones. Confidence improves only with repeatable results.
0 · Reply
Stcksnpr71
Stcksnpr71 Dec. 23 at 4:45 PM
$IVVD Nothing like a good after lunch turnaround. When are they gonna make bullish and bearish for the day signs
0 · Reply
www_larval_com
www_larval_com Dec. 23 at 4:42 PM
Dur-dur look @ $IVVD just dropped -3% lower to -2% (~3Mv) a moment ago, 01/16 options, follow for more volatility.
0 · Reply
Skynet7
Skynet7 Dec. 23 at 3:23 PM
$IVVD yes!!
0 · Reply
JohnTrack
JohnTrack Dec. 23 at 3:20 PM
$IVVD just observing, staying patient!
0 · Reply
Latest News on IVVD
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Dec 23, 2025, 7:05 AM EST - 2 days ago

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Dec 23, 2025, 7:01 AM EST - 2 days ago

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 7:01 AM EST - 4 weeks ago

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

Nov 24, 2025, 7:01 AM EST - 4 weeks ago

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination

Nov 18, 2025, 3:49 PM EST - 5 weeks ago

Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination

Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Nov 18, 2025, 8:23 AM EST - 5 weeks ago

Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

HD HP

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 17, 2025, 10:40 PM EST - 5 weeks ago

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

Invivyd Announces Proposed Public Offering of Common Stock

Nov 17, 2025, 4:01 PM EST - 5 weeks ago

Invivyd Announces Proposed Public Offering of Common Stock

Invivyd, Inc. (IVVD) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 11:36 AM EST - 6 weeks ago

Invivyd, Inc. (IVVD) Q3 2025 Earnings Call Transcript

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:01 AM EST - 7 weeks ago

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

Nov 3, 2025, 4:01 PM EST - 7 weeks ago

Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

Invivyd, Inc. (IVVD) Discusses REVOLUTION Clinical Program and Development of VYD2311 Antibody for COVID Prevention Transcript

Oct 30, 2025, 11:36 PM EDT - 7 weeks ago

Invivyd, Inc. (IVVD) Discusses REVOLUTION Clinical Program and Development of VYD2311 Antibody for COVID Prevention Transcript

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Oct 28, 2025, 7:01 AM EDT - 2 months ago

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Oct 6, 2025, 7:01 AM EDT - 2 months ago

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Appoints Paul B. Bolno, M.D.

Sep 24, 2025, 4:01 PM EDT - 3 months ago

Invivyd Appoints Paul B. Bolno, M.D.

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

Sep 17, 2025, 7:01 AM EDT - 3 months ago

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Sep 4, 2025, 7:01 AM EDT - 4 months ago

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Invivyd: Superior COVID Prophylaxis; Eventual Winner Regardless Of Trump Admin Anti-Vaccine Actions

Aug 29, 2025, 9:55 AM EDT - 4 months ago

Invivyd: Superior COVID Prophylaxis; Eventual Winner Regardless Of Trump Admin Anti-Vaccine Actions

Invivyd to Participate in Upcoming Investor Conferences

Aug 27, 2025, 7:01 AM EDT - 4 months ago

Invivyd to Participate in Upcoming Investor Conferences

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Aug 22, 2025, 12:00 PM EDT - 4 months ago

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Aug 20, 2025, 11:58 PM EDT - 4 months ago

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Aug 18, 2025, 4:32 PM EDT - 4 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 14, 2025, 4:49 PM EDT - 4 months ago

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Aug 14, 2025, 4:47 PM EDT - 4 months ago

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 23, 2025, 7:01 AM EDT - 5 months ago

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Jul 21, 2025, 7:05 AM EDT - 5 months ago

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 2, 2025, 7:01 AM EDT - 6 months ago

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Jun 26, 2025, 7:01 AM EDT - 6 months ago

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

May 27, 2025, 7:01 AM EDT - 7 months ago

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

May 23, 2025, 7:01 AM EDT - 7 months ago

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

May 21, 2025, 9:30 AM EDT - 7 months ago

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

Invivyd, Inc. (IVVD) Q1 2025 Earnings Call Transcript

May 15, 2025, 11:08 AM EDT - 7 months ago

Invivyd, Inc. (IVVD) Q1 2025 Earnings Call Transcript

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025, 7:01 AM EDT - 8 months ago

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

May 14, 2025, 7:01 AM EDT - 8 months ago

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 13, 2025, 7:01 AM EDT - 8 months ago

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

May 12, 2025, 7:01 AM EDT - 8 months ago

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

May 8, 2025, 7:01 AM EDT - 8 months ago

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Apr 21, 2025, 7:01 AM EDT - 8 months ago

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Mar 26, 2025, 4:15 PM EDT - 9 months ago

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Mar 20, 2025, 8:01 AM EDT - 10 months ago

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Mar 5, 2025, 7:05 AM EST - 10 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients

Feb 24, 2025, 9:20 AM EST - 10 months ago

FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Feb 24, 2025, 7:05 AM EST - 10 months ago

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Feb 10, 2025, 7:00 AM EST - 11 months ago

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

Feb 5, 2025, 9:30 AM EST - 11 months ago

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

I See The Bull Case For Invivyd, But I'm Not Married To It

Feb 4, 2025, 3:55 PM EST - 11 months ago

I See The Bull Case For Invivyd, But I'm Not Married To It

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

Feb 3, 2025, 6:55 AM EST - 11 months ago

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

Jan 27, 2025, 7:01 AM EST - 11 months ago

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Jan 10, 2025, 7:01 AM EST - 1 year ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 2:15 PM EST - 1 year ago

Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript

RunnerSignals
RunnerSignals Dec. 24 at 9:29 PM
Comeback Kings Watch $TMC $IVVD $SES $SGML $LODE They tagged the lows, shook it off, and finished higher
0 · Reply
SpecialOfficer
SpecialOfficer Dec. 24 at 3:58 PM
$IVVD not even 6,000 followers We early folks
0 · Reply
SpecialOfficer
SpecialOfficer Dec. 24 at 3:52 PM
$IVVD looks solid!! Picked up a few thousand shares 😝
0 · Reply
gb2017384
gb2017384 Dec. 24 at 3:06 PM
$IVVD THIS WHAT YOU GET AFTER A STRONG BUY RATING THE USUAL SUCKER BET$$$$
0 · Reply
JarvisFlow
JarvisFlow Dec. 24 at 11:01 AM
BTIG updates rating for Invivyd ( $IVVD ) to Buy, target set at 10.
0 · Reply
ExecutionerRex
ExecutionerRex Dec. 24 at 10:10 AM
$IVVD Forward visibility remains uneven as execution velocity aligns with stated operational milestones. Confidence improves only with repeatable results.
0 · Reply
Stcksnpr71
Stcksnpr71 Dec. 23 at 4:45 PM
$IVVD Nothing like a good after lunch turnaround. When are they gonna make bullish and bearish for the day signs
0 · Reply
www_larval_com
www_larval_com Dec. 23 at 4:42 PM
Dur-dur look @ $IVVD just dropped -3% lower to -2% (~3Mv) a moment ago, 01/16 options, follow for more volatility.
0 · Reply
Skynet7
Skynet7 Dec. 23 at 3:23 PM
$IVVD yes!!
0 · Reply
JohnTrack
JohnTrack Dec. 23 at 3:20 PM
$IVVD just observing, staying patient!
0 · Reply
prismmarketview
prismmarketview Dec. 23 at 3:14 PM
Invivyd (NASDAQ: $IVVD) won FDA Fast Track status for VYD2311, a long‑acting COVID‑19 prevention antibody, and has begun the pivotal DECLARATION Phase 3 trial in high‑risk adults and teens, with results targeted for mid‑2026. https://prismmarketview.com/invivyd-receives-fda-fast-track-designation-for-covid-19-prevention-antibody/
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Dec. 23 at 2:37 PM
$IVVD https://clinicaltrials.gov/study/NCT07298434?intr=VYD2311
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 23 at 2:36 PM
$IVVD
0 · Reply
briefingcom
briefingcom Dec. 23 at 2:23 PM
$IVVD: Invivyd earns fast track designation for VYD2311, a vaccine-alternative antibody to prevent COVID https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20251223070614IVVD&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
1 · Reply
topstockalerts
topstockalerts Dec. 23 at 1:34 PM
Invivyd said the U.S. Food and Drug Administration has granted Fast Track designation to VYD2311, its monoclonal antibody candidate for COVID-19 prevention. The program targets individuals at higher risk of severe disease and is positioned as a vaccine alternative. Fast Track status is intended to speed development and regulatory review for therapies addressing serious conditions with unmet medical needs. The company has launched DECLARATION, a Phase 3 clinical trial supporting a BLA submission, with preliminary data from 1,770 participants expected by mid-2026. VYD2311 will be administered via intramuscular injection, either as single-dose or monthly dosing. Invivyd said VYD2311 was developed using its proprietary integrated technology platform, designed to generate antibodies that can potentially remain effective against evolving viral variants. $IVVD
0 · Reply
JohnTrack
JohnTrack Dec. 23 at 12:57 PM
$IVVD Fast track win! https://www.rapidticker.com/news/ivvd-invivyd-earns-fast-track-designation-f10f9e
0 · Reply
AdLucrum
AdLucrum Dec. 23 at 12:48 PM
$IVVD
0 · Reply
DARKP00L
DARKP00L Dec. 23 at 12:03 PM
$IVVD 07:02 on Dec. 23 2025 Invivyd Initiates DECLARATION Trial Evaluating VYD2311, Investigational Vaccine-Alternative Monoclonal Antibody Candidate For Prevention Of COVID #tradeideas
0 · Reply
testedprofit
testedprofit Dec. 23 at 4:11 AM
$IVVD
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 23 at 3:15 AM
$IVVD RSI: 73.68, MACD: 0.1083 Vol: 0.16, MA20: 2.36, MA50: 2.11 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
crett
crett Dec. 22 at 10:02 PM
$IVVD no bears rumbling. Good sign
0 · Reply
Sw1ngb0t
Sw1ngb0t Dec. 22 at 9:48 PM
$IVVD $3.43+
0 · Reply